Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma

Annals of Hematology

Volumn 90, Issue 12, 2011, Pages 1441-1447

  Krejci, Marta ^a   Gregora, Evzen ^b   Straub, Jan ^c   Minarik, Jiri ^d   Scudla, Vlastimil ^d   Adam, Zdenek ^a   Krivanova, Andrea ^a   Pour, Ludek ^a   Zahradova, Lenka ^a   Buchler, Tomas ^e   Mayer, Jiri ^a   Hajek, Roman ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^e CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Bortezomib; Multiple myeloma; Thalidomide

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; M PROTEIN; MELPHALAN; THALIDOMIDE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD TOXICITY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME ADDITION; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFICACY; DRUG RESPONSE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INFECTION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROLOGIC DISEASE; NEUROTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84355163133     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1206-3     Document Type: Article

References (23)

1. H Ludwig M Beksac J Blade, et al. 2010 Current multiple myeloma treatment strategies with novel agents: a European perspective Oncologist 15 6 25 20086168 10.1634/theoncologist.2009-0203 1:CAS:528:DC%2BC3cXivVakt7c%3D
2. A Palumbo S Bringhen AM Liberati, et al. 2008 Oral melphalan, prednisone and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial Blood 112 3107 3114 18505783 10.1182/blood-2008-04- 149427 1:CAS:528:DC%2BD1cXht1Omur7P
3. T Facon JY Mary C Hulin, et al. 2007 Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial Lancet 370 1209 1218 17920916 10.1016/S0140-6736(07) 61537-2 1:CAS:528:DC%2BD2sXhtFehsr%2FN (Pubitemid 47516593)
4. C Hulin T Facon P Rodon, et al. 2009 Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma.: IFM 01/01 trial J Clin Oncol 27 3664 3670 19451428 10.1200/JCO.2008.21.0948 1:CAS:528:DC%2BD1MXhtVOnu7bJ
5. JF San Miguel R Schlag NK Khuageva, et al. 2008 Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma N Engl J Med 359 906 917 18753647 10.1056/NEJMoa0801479 1:CAS:528:DC%2BD1cXhtVGms77K
6. JP Laubach A Mahindra CS Mitsiades, et al. 2009 The use of novel agents in the treatment of relapsed and refractory multiple myeloma Leukemia 23 2222 2232 19741729 10.1038/leu.2009.179 1:CAS:528:DC%2BD1MXhsFKns7bK
7. MC Minemma E van der Spek NW van de Donk HM Lokhorst 2010 New developments in the treatment of patients with multiple myeloma Neth J Med 68 24 32
8. B Durie S Salmon 1975 A clinical staging system for multiple myeloma Cancer 36 842 854 1182674 10.1002/1097-0142(197509)36:3<842::AID- CNCR2820360303>3.0.CO;2-U 1:STN:280:DyaE28%2FktFCqtA%3D%3D
9. PR Greipp J San Miguel BG Durie, et al. 2005 International staging system for multiple myeloma J Clin Oncol 23 3412 3420 15809451 10.1200/JCO.2005.04.242
10. J Blade D Samson D Reece, et al. 1998 Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT Br J Haematol 102 1115 1123 9753033 10.1046/j.1365-2141.1998.00930.x 1:STN:280:DyaK1cvitl2mtw%3D%3D (Pubitemid 28435189)
11. BG Durie JL Harousseau JS Miguel, et al. 2006 International uniform response criteria for multiple myeloma Leukemia 20 1467 1473 16855634 10.1038/sj.leu.2404284 1:STN:280:DC%2BD28rgt1aqtA%3D%3D (Pubitemid 44264086)
12. SK Kumar SV Rajkumar A Dispenzieri, et al. 2008 Improved survival in multiple myeloma and the impact of novel strategies Blood 111 2516 2520 17975015 10.1182/blood-2007-10-116129 1:CAS:528:DC%2BD1cXivFaktrk%3D
13. van de Donk NW, Lokhorst HM, Dimopoulos M et al (2011) Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev (in press)
14. A Kumar I Hozo K Wheatley B Djulbegovic 2011 Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systemic review Am J Hematol 86 18 24 21120867 10.1002/ajh.21904 1:CAS:528:DC%2BC3MXhs1alsbw%3D
15. AA Chanan-Khan S Giralt 2010 Importance of achieving a complete response in multiple myeloma, and the impact of novel agents J Clin Oncol 28 2612 2624 20385994 10.1200/JCO.2009.25.4250 1:CAS:528:DC%2BC3cXotVyjtrc%3D
16. BG Durie 2010 Role of new treatment approaches in definnig treatment goals in multiple myeloma-the ultimate goal is extended survival Cancer Treat Rev 36 Suppl.2 S18 S23 20472184 10.1016/S0305-7372(10)70008-6
17. E Kastritis K Zervas A Symeonidis, et al. 2009 Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GSMG) Leukemia 23 1152 1157 19225533 10.1038/leu.2008.402 1:CAS:528:DC%2BD1MXntFygtLw%3D
18. M Roussou E Kastritis D Christoulas, et al. 2010 Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents Leuk Res 34 1395 1397 20510452 10.1016/j.leukres.2010.04.024 1:CAS:528:DC%2BC3cXhtV2itLfF
19. P Nemec Z Zemanova H Greslikova, et al. 2010 Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy Biol Blood Marrow Transplant 16 548 554 20005965 10.1016/j.bbmt.2009.11.025 1:CAS:528:DC%2BC3cXksl2gurY%3D
20. J Blade MT Cibeira C Fermandez de Larrea L Rosinol 2010 Multiple myeloma Ann Oncol 21 313 319 10.1093/annonc/mdq363
21. H Chang Y Trieau X Qi, et al. 2007 Bortezomib therapy response is independent on cytogenetic abnormalities in relapsed/refractory multiple myeloma Leuk Res 31 779 782 16996589 10.1016/j.leukres.2006.08.002 1:CAS:528: DC%2BD2sXmtlantbg%3D (Pubitemid 46855891)
22. PG Richardson B Barlogie J Berenson, et al. 2005 Clinical factors predictive of outcome with bortezomib in patiens with relapsed, refractory multiple myeloma Blood 106 2977 2981 16020506 10.1182/blood-2005-02-0691 1:CAS:528:DC%2BD2MXht1Wntr%2FM (Pubitemid 41565888)
23. S Jagannath PG Richarsdon P Sonneveld, et al. 2007 Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials Leukemia 21 151 157 17096017 10.1038/sj.leu.2404442 1:CAS:528: DC%2BD28XhtlSqur3O (Pubitemid 44921846)